OraQuick CLIA Waiver Study Cleared; CDC Official Reflects On Rapid HIV Tests
This article was originally published in The Gray Sheet
Executive Summary
OraSure will initiate a three-site, 75-subject protocol by the end of January to support a CLIA waiver application for the OraQuick rapid HIV test
You may also be interested in...
OraSure OraQuick
Rapid HIV-1 antibody test is granted CLIA waived status - expanding its availability to about 100,000 U.S. sites, including physician offices and HIV counseling centers. PMA approval of the 20-minute, whole-blood fingerprick test in November limited use to the roughly 38,000 domestic CLIA-approved labs that perform moderate complexity testing. The formal CLIA waiver application submission to FDA, one day before approval Jan. 31, included data confirming that 102 untrained users could administer the test. "Ensuring the widespread availability of a rapid HIV test to outreach services in communities where people are at high risk of HIV is vital to the public health," HHS Secretary Tommy Thompson states. Clinical trials showed 99.6% sensitivity and 100% specificity (1"The Gray Sheet" Jan. 6, 2003, p. 28)...
OraSure OraQuick
Rapid HIV-1 antibody test is granted CLIA waived status - expanding its availability to about 100,000 U.S. sites, including physician offices and HIV counseling centers. PMA approval of the 20-minute, whole-blood fingerprick test in November limited use to the roughly 38,000 domestic CLIA-approved labs that perform moderate complexity testing. The formal CLIA waiver application submission to FDA, one day before approval Jan. 31, included data confirming that 102 untrained users could administer the test. "Ensuring the widespread availability of a rapid HIV test to outreach services in communities where people are at high risk of HIV is vital to the public health," HHS Secretary Tommy Thompson states. Clinical trials showed 99.6% sensitivity and 100% specificity (1"The Gray Sheet" Jan. 6, 2003, p. 28)...
CLIA Waiver, Oral Fluid Claim Next For HHS-Backed OraQuick Rapid HIV Test
OraSure and FDA are discussing a CLIA waiver protocol the company has submitted for its OraQuick rapid HIV diagnostic test, which gained premarket approval Nov. 7